The global preterm birth prevention and management market was valued at USD 1.8 billion in 2024 and is expected to exhibit growth at a CAGR of 7.7% from 2025 to 2034. The market growth is attributed to the increasing preterm birth rates, advancements in medical technology, rising prevalence of maternal risk factors, and growing focus on neonatal care, among other contributing factors.
The preterm birth remains a primary cause of neonatal morbidity and mortality worldwide. For instance, according to the World Health Organization (WHO), an estimated 15 million babies are born preterm each year, and this number is rising. Additionaly, in 2022, preterm birth complications were responsible for approximately 1 million deaths in children under five years. The increasing incidence of preterm births has created a higher demand for prevention and management solutions, driving market expansion.
Moreover, technological innovations in prenatal care, such as improved diagnostic tools, monitoring systems, and treatments, are enabling better management of high-risk pregnancies, leading to enhanced outcomes for preterm infants
Preterm birth prevention and management refers to the strategies and medical interventions aimed at preventing or managing premature births (before 37 weeks of gestation). This includes the use of therapies like progesterone, tocolytics, corticosteroids, and magnesium sulfate to delay labor, promote fetal lung maturity, and manage complications.
The market is experiencing several market trends that are shaping its growth and development. Factors such as increasing use of digital health solutions, growth in personalized medicine, and increased research and development in drug therapy, among other factors are boosting the industry growth.
Based on therapy type, the market is segmented as progesterone therapy, corticosteroid therapy, tocolytic therapy, antibiotics therapy, heparin prophylaxis therapy, and other therapy types. The progesterone therapy segment is expected to drive business growth and expand at a CAGR of 8%, reaching over USD 1.5 billion by 2034.
Based on route of administration, the market is segmented into parenteral, oral, and topical. The parenteral segment is expected to drive business growth and expand at a CAGR of 7.6%, reaching over USD 2.7 billion by 2034.
Based on distribution channel, the market is classified into brick and mortar and e-commerce. The brick and mortar segment dominated the market with a revenue share of 82.5% in 2024.
U.S. preterm birth prevention and management market accounted for USD 671.6 million in 2024 and is anticipated to grow at a CAGR of 7.2% between 2025 to 2034 period.
Germany preterm birth prevention and management market is projected to grow remarkably in the coming years.
China holds a dominant position in the Asia Pacific preterm birth prevention and management market.
The market is characterized by a mix of pharmaceutical companies, medical device manufacturers, and healthcare providers offering a range of products and services. Key players focus on developing advanced treatments, such as progesterone therapies, tocolytics, and diagnostic tools for early detection. Additionally, hospitals and specialized maternal care centers play a crucial role in providing management solutions. The market is highly competitive, with companies investing in R&D and strategic partnerships to improve preterm birth prevention strategies and enhance maternal and neonatal health outcomes.
Prominent players operating in the preterm birth prevention and management industry include: